Mayne Pharma: Doryx™ Capsules & Tablets

By: Mayne Pharma (cda)  09-12-2011
Keywords: health care, tablets, Benefits Scheme

Doryx™ capsules and tablets are delayed release oral formulations of doxycycline (a tetracycline class of antibiotic), that can be used treat certain types of infections, as adjunctive treatment of severe acne and as an anti-malarial.

Doryx™ capsules and tablets contains enteric-coated pellets of doxycycline hyclate and is the only delayed release pelletised doxycycline product on the market.

Pellets are formulated to delay the release of doxycycline until the product reaches the small intestine thus reducing the potential for gastrointestinal side effects such as nausea and vomiting compared to conventional doxycycline products.

Doryx™ delayed-release tablets are available in 75mg, 100mg and 150mgs. Doryx™ delayed-release capsules are available in 50mg and 100mg.

Doryx™ capsules are currently licensed and sold in Australia and Singapore. Doryx™ tablets are licensed and sold in United States. Opportunities remain for licensing in a significant number of international territories.

Mayne Pharma offers Doryx™ capsules and tablets on the Pharmaceutical Benefits Scheme (PBS) in Australia.

This product is prescription only. Your doctor will advise you whether this product is suitable for you. Always read the label. Use only as directed. If symptoms persist see your health care professional.

Further Information

Keywords: Benefits Scheme, health care, Pharmaceutical Benefits Scheme, tablets,

Contact Mayne Pharma (cda)


Print this page

Other products and services from Mayne Pharma (cda)


Mayne Pharma: Eryc™ / Erymax™ Capsules

Indicated for the treatment of a wide variety of bacterial infections, Eryc™ erythromycin is formulated to protect erythromycin degrading in the acidic environment of the stomach, for optimal absorption in the intestine. Eryc™ erythromycin capsules are currently licensed and sold in Australia, Canada, Sweden and the United Kingdom. Eryc™ capsules are a delayed release erythromycin produced by Mayne Pharma using proprietary pellet technology.


Mayne Pharma: Astrix™ Capsules & Tablets

Astrix™ aspirin tablets are an immediate release low-dose form of aspirin indicated for inhibition of platelet aggregation to help prevent heart attack and stroke in patients with known cardiovascular and cerebrovascular disease. Your doctor will advise you whether using Astrix™ capsules or tablets as part of an overall program to manage the risk of heart attack or stroke is suitable for you.